morphosys.com (MOR): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Optimized component deliveries for antibodies eliminate test failures, supporting the business valuation via EV/EBITDA, where the current level is . Stable royalties for lymphoma treatment ensure financial stability for MorphoSys AG (MOR), while the integration of unique libraries into global partnerships solidifies its status as an innovator in tumor therapy.
MOR (morphosys.com): analytical breakdowns and indicator data
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
- financial results and valuation multiples details:
MOR - Company Net Income|Expected Profit MorphoSys AG|MOR - Business Payback Period|Projected Price to Earnings MorphoSys AG|MOR - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MorphoSys Corporation|MOR - Operating income before deduction of amortization|Net earnings per share for the last 12 months MorphoSys|MOR - Earnings per share for the trailing year|Quarterly EPS earnings growth morphosys.com|MOR - Earnings growth in current year|Earnings growth forecast for next year MorphoSys AG
Summary company analysis:MOR (MorphoSys Corp)
Assessing the reliability of equity assets begins with analyzing a business's ability to service its obligations. This ratio correlates the total enterprise value of the company with its operating profit before depreciation and amortization, measuring the actual debt load. For MorphoSys AG (MOR), support from a Swiss behemoth and patent protection mitigate risks, which is reflected in the stability of the EV/EBITDA metric including depreciation and debt.
Direct competitors
BeiGene Corp - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Halozyme Corp HALO|RVMD - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation AAPG (ascentage.com)|CGON: EV/EBITDA Multiple|Company Value to EBITDA UroGen Pharma Ltd (URGN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bicara Bio|Enterprise Value to EBITDA Ratio Personalis Genomics (PSNL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Erasca, Inc. (ERAS)|DCTH - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Y-mAbs Therapeutics, Inc. YMAB|Business Value to Operating Income Before Depreciation AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ARAY|SLS: EV/EBITDA Multiple|actuatetherapeutics.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology|Company Value to EBITDA TuHURA HURA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara (TARA)|Total Company Value to Operating Income Before Depreciation Ratio Fate Pharma|Aadi Bioscience - Enterprise Value to EBITDA Ratio|TScan Therapeutics Inc (TCRX) - Company Value to EBITDA|CSBR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio XBiotech Inc. XBIT|CVM (cel-sci.com) - Enterprise Value to EBITDA Ratio|OS Therapies, Inc. - Business Value to Operating Income Before Depreciation|RADX (Radiopharm Theranostics) - EV/EBITDA Multiple|EV/EBITDA Multiple Artiva|EV/EBITDA Multiple ANL|Veru Inc (VERU) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Tx TPST|XLO - Enterprise Value to EBITDA Ratio|RENB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Mural Oncology plc|kairospharma.com (KAPA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OnKure Therapeutics - Business Value to Operating Income Before Depreciation|GDTC (CytoMed Therapeutics Ltd) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Curis Corp (CRIS)|EV/EBITDA Multiple APLM|EV/EBITDA Multiple tharimmune.com (THAR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Advanced Biomed ADVB|GNPX: Enterprise Value to Operating Income Before Depreciation|Calidi Bio - EV/EBITDA Multiple|sunshinebiopharma.com (SBFM) - Enterprise Value to EBITDA Ratio|XBIO: EV/EBITDA Multiple|Company Value to EBITDA salariuspharma.com (SLRX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Purple Biotech Ltd.|AONC: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio BGNE (BeOne Medicines)|CKPT (Checkpoint Therapeutics Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ELEV (Elevation Oncology)|ICAD - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to EBITDA Ratio|NTBL - EV/EBITDA Multiple|viracta.com (VIRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NAYA Biosciences Corp - Business Value to Operating Income Before Depreciation|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
